Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If ...

Duke Human Vaccine Institute (DHVI) investigators used a technique called time-resolved, temperature-jump (TR, T-Jump) small-angle x-ray scattering (SAXS) to capture the spectacularly brief moment ...

A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

Researchers revealed that HIV integrase forms structural filaments within the viral capsid, enabling viral infectivity. The discovery uncovers a new drug target, opening possibilities for ...

Now two new studies led by TSRI scientists advance these efforts. The first describes a strategy to stabilize an important HIV structure and potentially create HIV lookalikes for large-scale vaccine ...

Researchers discovered antibody 007, which binds to the V3 glycan site on HIV-1, required for viral entry into immune cells. This antibody overcomes limitations of previous approaches, as it is not ...